A share of Dyne Therapeutics Inc. (NASDAQ:DYN) closed at $11.90 per share on Wednesday, up from $11.78 day before. While Dyne Therapeutics Inc. has overperformed by 1.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, DYN rose by 9.58%, with highs and lows ranging from $15.63 to $4.30, whereas the simple moving average jumped by 18.65% in the last 200 days.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
On July 20, 2022, Chardan Capital Markets started tracking Dyne Therapeutics Inc. (NASDAQ: DYN) recommending Buy. A report published by Raymond James on July 12, 2022, Initiated its previous ‘Outperform’ rating for DYN. Stifel also rated DYN shares as ‘Buy’, setting a target price of $29 on the company’s shares in an initiating report dated October 12, 2020. Piper Sandler Initiated an Overweight rating on October 12, 2020, and assigned a price target of $34. JP Morgan initiated its ‘Overweight’ rating for DYN, as published in its report on October 12, 2020. Jefferies’s report from October 12, 2020 suggests a price prediction of $47 for DYN shares, giving the stock a ‘Buy’ rating.
Analysis of Dyne Therapeutics Inc. (DYN)
Dyne Therapeutics Inc.’s future performance can be predicted by a variety of well-rounded types of analysis and research, with equity being one of the most crucial ones. The goal here is to ensure that your current return on equity of -58.30% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 11.10, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can be an extremely valuable indicator of volatility, and DYN is registering an average volume of 283.59K. On a monthly basis, the volatility of the stock is set at 8.08%, whereas on a weekly basis, it is put at 6.79%, with a gain of 0.34% over the past seven days. Furthermore, long-term investors anticipate a median target price of $25.00, showing growth from the present price of $11.90, which can serve as yet another indication of whether DYN is worth investing in or should be passed over.
How Do You Analyze Dyne Therapeutics Inc. Shares?
Besides checking the fundamentals, you should also know how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.50%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 87.60% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
Are institutional investors increasing their holdings in DYN shares?
The recent increase in stakes in DYN appears to be a result of several institutional investors and hedge funds increasing their positions. Deep Track Capital LP’s position in DYN has decreased by -9.02% in the first quarter. The company now owns 3,184,200 shares of the stock, with a value of $37.26 million, following the sale of -315,800 additional shares during the last quarter. Citadel Advisors LLC made another decreased to its shares in DYN during the first quarter, downing its stake by -0.02%.
At the end of the first quarter, BlackRock Fund Advisors increased its DYN holdings by 1.99% and now holds 2.14 million DYN shares valued at $25.0 million with the added 41643.0 shares during the period. DYN shares are owned by institutional investors to the tune of 87.60% at present.
